See more : Safe Bulkers, Inc. (SB) Income Statement Analysis – Financial Results
Complete financial analysis of Edgewise Therapeutics, Inc. (EWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edgewise Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nanjing Xinjiekou Department Store Co., Ltd. (600682.SS) Income Statement Analysis – Financial Results
- Kaira Can Company Limited (KAIRA.BO) Income Statement Analysis – Financial Results
- Delivra Health Brands Inc. (DHBUF) Income Statement Analysis – Financial Results
- AhnLab, Inc. (053800.KQ) Income Statement Analysis – Financial Results
- AirTrona International, Inc. (ARTR) Income Statement Analysis – Financial Results
Edgewise Therapeutics, Inc. (EWTX)
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| Gross Profit | -1.73M | -538.00K | -272.00K | -185.00K | -123.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.91M | 16.61M | 32.19M | 14.98M | 8.62M |
| General & Administrative | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Cost & Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Interest Income | 14.19M | 2.66M | 402.00K | 69.00K | 219.00K |
| Interest Expense | 0.00 | 4.02M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| EBITDA | -112.81M | -67.10M | -42.94M | -17.01M | -9.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -114.36M | -22.08M | -43.22M | -17.19M | -9.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.19M | 4.02M | 402.00K | 69.00K | 219.00K |
| Income Before Tax | -100.16M | -19.42M | -42.81M | -17.12M | -9.71M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.02M | -674.00K | -69.00K | -219.00K |
| Net Income | -100.16M | -15.40M | -42.14M | -17.05M | -9.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EPS Diluted | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
| Weighted Avg Shares Out (Dil) | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class oral, selective, cardiac...
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET. The presentation will be webcast...
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy...
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne. EDG-5506 is an investigational orally...
Insider Favorites: 7 Stocks with Bullish Buying Signals
While investors shouldn't get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it's difficult to tell what insider selling means.
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Source: https://incomestatements.info
Category: Stock Reports